For that reason, we conducted our proof‐of‐concept DIA study to assess the landscape of pediatric solid tumors for PD‐1/PD‐L1 immunotherapy analyzing high‐quality commercially available pediatric tissues from tumor resections acknowledging their limited clinical information, including lack of PD‐1/PD‐L1 therapeutic outcome. This evidence concerns the gene CD274 and neoplasm.